Acute Kidney Disease and Mortality in Acute Kidney Injury Patients with COVID-19.
COVID-19
acute kidney disease
acute kidney injury
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
06 Oct 2021
06 Oct 2021
Historique:
received:
01
09
2021
revised:
26
09
2021
accepted:
03
10
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
14
10
2021
Statut:
epublish
Résumé
The incidence of AKI in coronavirus disease 2019 (COVID-19) patients is variable and has been associated with worse prognosis. A significant number of patients develop persistent kidney damage defined as Acute Kidney Disease (AKD). There is a lack of evidence on the real impact of AKD on COVID-19 patients. We aim to identify risk factors for the development of AKD and its impact on mortality in COVID-19 patients. Retrospective analysis of COVID-19 patients with AKI admitted at the Centro Hospitalar Universitário Lisboa Norte between March and August of 2020. The Kidney Disease Improving Global Outcomes (KDIGO) classification was used to define AKI. AKD was defined by presenting at least KDIGO Stage 1 criteria for >7 days after an AKI initiating event. In 339 COVID-19 patients with AKI, 25.7% patients developed AKD ( AKD was significantly associated with in-hospital mortality in this population of COVID-19-AKI patients. Considering the significant risk of mortality in AKI patients, it is of paramount importance to identify the subset of higher risk patients.
Sections du résumé
BACKGROUND
BACKGROUND
The incidence of AKI in coronavirus disease 2019 (COVID-19) patients is variable and has been associated with worse prognosis. A significant number of patients develop persistent kidney damage defined as Acute Kidney Disease (AKD). There is a lack of evidence on the real impact of AKD on COVID-19 patients. We aim to identify risk factors for the development of AKD and its impact on mortality in COVID-19 patients.
METHODS
METHODS
Retrospective analysis of COVID-19 patients with AKI admitted at the Centro Hospitalar Universitário Lisboa Norte between March and August of 2020. The Kidney Disease Improving Global Outcomes (KDIGO) classification was used to define AKI. AKD was defined by presenting at least KDIGO Stage 1 criteria for >7 days after an AKI initiating event.
RESULTS
RESULTS
In 339 COVID-19 patients with AKI, 25.7% patients developed AKD (
CONCLUSIONS
CONCLUSIONS
AKD was significantly associated with in-hospital mortality in this population of COVID-19-AKI patients. Considering the significant risk of mortality in AKI patients, it is of paramount importance to identify the subset of higher risk patients.
Identifiants
pubmed: 34640618
pii: jcm10194599
doi: 10.3390/jcm10194599
pmc: PMC8509682
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
BMJ Open. 2015 Jan 06;5(1):e006497
pubmed: 25564144
PLoS One. 2020 Dec 9;15(12):e0243528
pubmed: 33296419
Crit Care Res Pract. 2012;2012:691013
pubmed: 23227318
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Adv Chronic Kidney Dis. 2020 Sep;27(5):365-376
pubmed: 33308501
Am J Kidney Dis. 2021 Apr;77(4):490-499.e1
pubmed: 33422598
Kidney Int Rep. 2020 Apr 09;5(6):935-939
pubmed: 32292867
Med Clin (Barc). 2021 Apr 9;156(7):324-331
pubmed: 33422296
Clin Kidney J. 2020 Sep 27;14(5):1379-1387
pubmed: 33959267
Am J Kidney Dis. 2021 Feb;77(2):204-215.e1
pubmed: 32961245
J Am Coll Surg. 2020 Sep;231(3):326-332
pubmed: 32585304
Blood Purif. 2021;50(4-5):520-530
pubmed: 33341806
Crit Care. 2021 Jan 25;25(1):37
pubmed: 33494766
Clin Kidney J. 2016 Apr;9(2):192-200
pubmed: 26985368
Kidney Int Rep. 2020 Apr 28;5(6):940-945
pubmed: 32346659
Clin J Am Soc Nephrol. 2013 Feb;8(2):194-202
pubmed: 23124779
Clin J Am Soc Nephrol. 2013 Jul;8(7):1070-8
pubmed: 23539228
J Am Soc Nephrol. 2020 Aug;31(8):1683-1687
pubmed: 32371536
Immun Inflamm Dis. 2021 Aug 26;:
pubmed: 34438471
Diabetes Care. 2009 Jan;32 Suppl 1:S13-61
pubmed: 19118286
J Ren Nutr. 2005 Jan;15(1):94-8
pubmed: 15648015
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Medicines (Basel). 2021 Jan 07;8(1):
pubmed: 33430296
Am J Trop Med Hyg. 2020 Dec;103(6):2164-2167
pubmed: 33124548
Tohoku J Exp Med. 2015;237(4):287-95
pubmed: 26607258
PLoS Med. 2020 Oct 30;17(10):e1003406
pubmed: 33125416
J Am Soc Nephrol. 2021 Jan;32(1):151-160
pubmed: 32883700
Med Clin (Barc). 2021 May 7;156(9):428-436
pubmed: 33627230
Clin J Am Soc Nephrol. 2011 Nov;6(11):2567-72
pubmed: 21903988
BMC Pulm Med. 2020 Nov 9;20(1):290
pubmed: 33167955
N Engl J Med. 2014 Jul 3;371(1):58-66
pubmed: 24988558
BMC Nephrol. 2019 Nov 21;20(1):427
pubmed: 31752748
Ren Fail. 2020 Nov;42(1):393-397
pubmed: 32340507
Pediatr Nephrol. 2020 May;35(5):799-806
pubmed: 31940070
J Clin Med. 2021 Mar 15;10(6):
pubmed: 33804100
Sci Rep. 2020 Sep 24;10(1):15636
pubmed: 32973230
Clin Nephrol. 2016 Jan;85(1):1-11
pubmed: 26636328
JAMA. 2003 May 21;289(19):2560-72
pubmed: 12748199
Am J Nephrol. 2020;51(10):786-796
pubmed: 33011717
Kidney Int. 2020 Jul;98(1):219-227
pubmed: 32327202
Clin Rheumatol. 2020 Jul;39(7):2085-2094
pubmed: 32474885
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Front Immunol. 2020 Jun 16;11:1441
pubmed: 32612615
Transfus Apher Sci. 2020 Dec;59(6):102926
pubmed: 32893135
J Med Virol. 2021 Mar;93(3):1478-1488
pubmed: 32813298
Braz J Infect Dis. 2021 Mar-Apr;25(2):101569
pubmed: 33736948
Kidney Int. 2020 Jul;98(1):228-231
pubmed: 32471639
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Kidney Int. 2020 Jul;98(1):209-218
pubmed: 32416116
Blood Purif. 2021;50(4-5):499-505
pubmed: 33291098
Tuberk Toraks. 2020 Dec;68(4):407-418
pubmed: 33448738
BMC Nephrol. 2020 Jul 31;21(1):318
pubmed: 32736541
J Clin Med. 2020 Jun 03;9(6):
pubmed: 32503180
Nat Rev Nephrol. 2017 Apr;13(4):241-257
pubmed: 28239173
Clin Nephrol. 2013 Mar;79(3):221-8
pubmed: 23253902
J Am Soc Nephrol. 2010 Feb;21(2):345-52
pubmed: 20019168
Kidney Int Rep. 2020 Mar 12;5(6):839-850
pubmed: 32518866
Int Urol Nephrol. 2017 Feb;49(2):295-302
pubmed: 27817055